Literature DB >> 24729113

Metastatic bone lesion due to methotrexate and etanercept 24 years after breast cancer treatment.

Shuichi Yano1.   

Abstract

A 72-year-old woman with rheumatoid arthritis presented with lumbar vertebral bone metastasis 24 years after mammectomy and radiotherapy for breast cancer. She was treated with prednisolone and methotrexate (MTX) for 11 months to which 10 mg of etanercept twice a week was added for a further 8 months. On the basis of this result, the possibility of a metastatic bone lesion appearing many years after cancer treatment should be considered when planning MTX and etanercept therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24729113      PMCID: PMC3987532          DOI: 10.1136/bcr-2013-202615

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

1.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

Review 2.  Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.

Authors:  Xavier Mariette; Marco Matucci-Cerinic; Karel Pavelka; Peter Taylor; Ronald van Vollenhoven; Rebecca Heatley; Claire Walsh; Richard Lawson; Alan Reynolds; Paul Emery
Journal:  Ann Rheum Dis       Date:  2011-09-01       Impact factor: 19.103

3.  Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K D Watson; M Lunt; L K Mercer; K L Hyrich; D P M Symmons
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

4.  Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

Authors:  Anja Strangfeld; Franka Hierse; Rolf Rau; Gerd-Ruediger Burmester; Brigitte Krummel-Lorenz; Winfried Demary; Joachim Listing; Angela Zink
Journal:  Arthritis Res Ther       Date:  2010-01-08       Impact factor: 5.156

5.  Disseminated breast cancer cells acquire a highly malignant and aggressive metastatic phenotype during metastatic latency in the bone.

Authors:  Carolyn G Marsden; Mary Jo Wright; Latonya Carrier; Krzysztof Moroz; Brian G Rowan
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

  5 in total
  1 in total

1.  Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment.

Authors:  Donna M Sosnoski; Robert J Norgard; Cassidy D Grove; Shelby J Foster; Andrea M Mastro
Journal:  Clin Exp Metastasis       Date:  2015-03-08       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.